A study investigating the effect of a new drug Zelasudil for people with IPF

Upcoming study
Expected to open September 2022
This study is currently recruiting
Expected to close April 2024
This study is closed
This study closed in April 2024
We will update this page with study results when available.
Information on study results are included below
This study closed in April 2024
Ask your healthcare team about taking part in research

What next?

Original listing:

What next?

Original listing:

About this study

The aim of the study is to learn about how the body responds to a new drug Zelasudil (RX007) and if it is effective in slowing disease progression in people living with IPF


What is involved?

You will be involved in the study for up to 12 weeks. You will be randomly assigned into different groups. One group will be given the drug, Zelasudil, whereas the other group will be given a placebo. A placebo does not contain any active ingredients of the study drug and is a lookalike medication. If you are in the group that is given the drug, it will be given at different doses, depending on the timepoint at which you take part in the study.

When you take part in the study, the researchers will carry out medical assessments such as blood pressure, pulse rate, respiration rate and temperature; ECG recordings; and blood tests to gain understanding of how your body responds to the drug. Lung function tests will also be carried out.

After the study has finished, you may be given an opportunity to take the study drug for an additional 12 weeks, if you would like to.

Summary of involvement

Up to 12 weeks

Taking a drug or placebo everyday

Medical assessments

Lung function tests

Can I take part?

You may be able to take part if you are aged between 40 and 80 years, and have a diagnosis of IPF within the last 5 years

In research studies, there are lots of different reasons why you may or may not be able to take part. These are known as inclusion and exclusion criteria (see list below). Only the research team will be able to fully determine whether you are able to take part in the study. You can withdraw at any point.

If you are not able to take part in this research study, there may be other opportunities for you to take part in different studies.

To find our more about other research opportunities visit our research finder main page.

You may be able to join this study if all of these apply:

Aged between 40 and 80 years

Diagnosis of IPF within the last 5 years

If taking nintedanib or pirfenidone, the participant must have been receiving treatment for at least 3 months, and on a stable dose for at least 4 weeks

Additional lung function criteria. These will be assessed by the research team

You will not be able to join the study of any of the following applies:

Currently or planning to receive treatment for IPF that is not approved for the disease

Lower respiratory tract infection requiring antibiotics within the last 4 weeks

Oxygen therapy for more than 15 hours per day

Acute exacerbation within the last 6 months

Diagnosis of connective tissue disease or interstitial pneumonia with autoimmune features

Other disease where life expectancy is less than 12 weeks

What difference could taking part make?

Taking part in this study will help researchers to understand if Zelasudil could be an effective treatment for patients with IPF. The study will help to gain greater understanding of the medication including safety and tolerability, along with how the body responds to the drug.

Where does the study take place?

Study locations








How to take part

If you would like to take part in this study or find out more information, please speak to your healthcare team to express your interest in research.

Further information

This page is a summary which provides information about an opportunity to participate in research. More detailed information about the study can be found via the following the links and through contacting the research team.

If you have any questions about this research study, please speak to your medical team.

This study is supported by

Redx Pharma
Simbec Research
Study ID number:

APF does not endorse or recommend any specific study. All responsibility for the study remains with the sponsors and investigators.

Every effort is made to keep these details up to date. If you are aware of any inaccuracies, please email research@actionpf.org